key: cord-0832242-eualps0x authors: Bérezné, Alice; Bougon, David; Blanc‐Jouvan, Florence; Gendron, Nicolas; Janssen, Cecile; Muller, Michel; Bertil, Sébastien; Desvard, Florence; Presot, Isabelle; Terrier, Benjamin; Chocron, Richard; Sanchez, Olivier; Helley, Dominique; Smadja, David M. title: Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay date: 2021-09-01 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12572 sha: 7a33fca41ece0677f68470bef3b5fafe3f9e7175 doc_id: 832242 cord_uid: eualps0x We report a case of a 62‐year‐old man who developed cerebral venous sinus thrombosis with subarachnoid hemorrhage and concomitant thrombocytopenia, which occurred 13 days after ChAdOx1 nCov‐19 injection. The patient died in the intensive care unit after heparin infusion and platelet transfusion. The key clinical purpose of this case report is to better understand how to confirm vaccine‐induced immune thrombotic thrombocytopenia (VITT). VITT diagnosis was made using (14)C‐serotonin release and flow cytometry evaluating activation and platelet microvesicles on washed platelets. Four control patients were examined: a patient with heparin‐induced thrombocytopenia (HIT), two patients with thrombotic events without thrombocytopenia after ChAdOx1 nCov‐19 or BNT162b2, and a patient with suspected HIT and an excluded diagnosis. We evidenced in the VITT case a high level of IgG anti–platelet factor 4–heparin antibodies associated with a high level of platelet activation in the absence of heparin. Conversely, the functional assays were negative in the patients with thrombosis without thrombocytopenia. • Vaccine-induced immune thrombotic thrombocytopenia (VITT) can appear after vaccination. • VITT is characterized by positive antiplatelet factor 4 antibodies. • Heparin infusion and platelet transfusion induce worsening of the disease. • We confirm that VITT has a specific profile using specific platelet activation assays. Respiratory tract infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a systemic inflammatory disease (coronavirus disease 2019 ) associated with coagulopathy and endothelial damage that lead to microthrombosis. [1] [2] [3] [4] [5] [6] [7] The COVID-19 pandemic is still poorly controlled, and mass vaccination programs are ongoing to lower both the SARS-CoV-2 circulation and the pressure on health systems. [8] [9] [10] We previously analyzed the frequency of anti-COVID-19 vaccination thrombotic events reported in the World Health Organization Global Database for Individual Case Safety Reports (VigiBase). It was found that thrombotic events, including cerebral venous thrombosis, might occur in association with all three vaccines available in Europe, without evidence of a link between the vaccines and the thrombotic events. 11 However, three studies recently described thrombotic thrombocytopenia after ChAdOx1 nCov-19 (vaxzevria, the Oxford-AstraZeneca vaccine) respectively in 11, 5, and 23 patients. [12] [13] [14] Moreover, Muir et al 15 This rare syndrome has been called vaccine-induced immune thrombotic thrombocytopenia (VITT) or thrombosis with thrombocytopenia syndrome as defined by the World Health Organization. We report here a 62-year-old French man admitted into an emergency department with epigastric discomfort and severe right-sided abdominal pain occurring 11 days after his first intramuscular injection with the ChAdOx1 nCov-19 vaccine. The patient's body mass index was 32.7 kg/m 2 , and he had no history of thrombosis, nor did his family. He had a medical history of diabetes mellitus, hypereosinophilic asthma treated with benralizumab, and obstructive sleep apnea. This patient was immediately transferred to the gastroenterology unit for endoscopic retrograde cholangiopancreatography for suspected bile-duct stone migration. He showed no fever, and physical examination was mundane, with the exception of an intense tenderness on abdominal palpation. Upon admission, laboratory examination revealed a moderate increase in C-reactive protein to 56 mg/L (normal value, <5 mg/L), moderate cytolysis without cholestasis, leukocyte count of 21.3 × 10 9 /L, hemoglobin level of 174 g/L, and platelet count of 100 × 10 9 /L. A SARS-CoV-2 reversetranscriptase polymerase chain reaction assay of a nasopharyngeal swab was negative. Abdominal computed tomography (CT) imaging was suggestive of bile-duct stone migration due to macrolithiasis in the gallbladder. The following day (day 12), the platelet count had fallen to 10 × 10 9 /L. The patient died a few hours later, at day 13 following ChAdOx1 nCov-19 injection. The results of the autopsy confirmed death by superior sagittal sinus thrombosis with subarachnoid hemorrhage and a rupture of the thrombosed cortical vein. The autopsy also confirmed multivisceral thrombosis in small, medium, and large vessels in many organs, such as the heart ( Figure 1A ), the liver ( Figure 1B ), the kidney, and the spleen, accompanied by typical lesions of ischemic myocardial and hepatic necrosis. Macroscopically, the heart and liver appeared heterogeneous. Microscopically, in the liver, we observed the presence of steatosis (30%), central lobular necrosis, and vascular and endothelial thrombi in medium-sized vessels. In the heart, there was gross morphologic evidence of early myocardial infarction, with an organizing thrombus in a branch of the left circumflex coronary. A standard immunohistochemical method detected a heterogeneous desmin depletion. The blood vessels had clumped red blood cells in the lumen, forming fibrino-cruoric microthrombi. Informed consent was received from the patient's family. All specific biological explorations were conducted following the death of this patient, as VITT was not a clearly defined syndrome during the hospitalization of this patient in March 2021. Serum samples were obtained from this patient at day 13 for exploration by platelet-activation assays. We used a standard enzyme-linked immunosorbent assay to detect IgG platelet factor 4 (PF4)-heparin antibodies (anti-PF4/H). The presence of IgG anti--PF4/H in the patient's plasma was evaluated by ELISA (Zymutest HIA, Hyphen Biomed, Neuville-sur-Oise, France), according to the manufacturer's protocol. An optical density (OD) of 0.5 was defined as the positive cutoff value. We evaluated platelet-activating antibodies with the 14 C-serotonin release assay (SRA) as previously described. [16] [17] [18] We also measured platelet-activating antibodies by flow cytometric assay based on a platelet microvesicle assay (PMA), which detected the activation of washed platelets induced by activating heparin-dependent antibodies. 19 The PMA was performed as previously described by Maeda et al 19 by the evaluation of plateletactivating profiles, which detects the activation of washed platelets induced by activating antibodies in plasma or serum. In the SRA and PMA, platelet activation was challenged by an Fc-receptor-blocking monoclonal antibody (anti-CD32/FcγRIIA, clone IV.3; STEMCELL Technologies, Vancouver, BC, Canada) to confirm FcγRIIA engagement in platelets. 12 Blood from healthy donors selected as platelet donors known to react well in the SRA was used, as previously suggested by Warkentin et al. 18 These normal healthy donors had been free from aspirin and nonsteroidal anti-inflammatory drugs for at least 10 days. The healthy donors were known to react well to SRA, and their washed platelets were used at a platelet concentration of Figure 2B and 2C for patients B and C, respectively). Patient A showed increased reactivity with buffer control and UFH 0.1 and 0.5 U/mL. Platelet reactivity was blocked by UFH 100 U/mL and also when the blocking monoclonal antibody against FcγRIIa was added to UFH 0.1 U/mL, as for patient C with HIT ( Figure 2C ). We confirmed with the PMA (Figure 3 High levels of IgG anti-PF4/H were found to be associated with positivity of functional testing by flow cytometry evaluating activated-platelet and platelet microvesicles on washed platelets, in contrast to a previous report using P-selectin evaluation of platelets. 14 In contrast to patients with classical HIT, the functional assays (PMA and SRA) of our patient were not dependent on low doses of UFH but were sensitive to inhibition by high-dose UFH or by the Fc-receptor-blocking monoclonal antibody. This patient received UFH therapy before tested blood samples were obtained. Even if we cannot rule out the presence of previous circulating complexes, containing antibodies bound to PF4 and heparin, the severe thrombocytopenia before UFH introduction allows us to be confident with our results. The results of the PMA suggest that the a specificity close to those classically observed in HIT. Our findings confirm that a syndrome similar to HIT may occur in a subgroup of patient's following ChAdOx1 nCov-19 injection. Strikingly, the case described here is a man >60 years, and, when associated with other cases described by Scully et al, 14 we can probably affirm that VITT can be suspected in all ages, as described in reports from the Kingdom (report from May 13, 2021) . VITT incidence appears to be probably very low, and the beneficial effect of anti-COVID-19 vaccination fully outweighs this rare adverse effect. We confirm here also the specificity of this anti-PF4-related thrombosis by exploring IgG anti-PF4/H in two other patients with venous thrombosis after COVID-19 vaccination (one receiving the BNT162b2 and the other receiving the ChAdOx1 nCov-19 injection). Of note, these two venous thrombotic events were not associated with thrombocytopenia. This association between thrombosis and immune thrombocytopenia was observed only with the ChAdOx1 nCov-19 and Ad26.COV2.S COVID-19 vaccines, whereas thrombotic events have been observed with all available vaccines in Europe, probably linked more to the population that the vaccination itself. 11 In the SRA and PMA, platelet activation was inhibited by the Fc-receptor-blocking monoclonal antibody (anti-CD32), confirming the engagement of FcγRIIA in platelets and allowing us to confirm antibody-dependent platelet activation and to exclude a nonspecific mechanism, such as inflammation. 21 This case reports VITT in a man >60 years old and a flow cytometry assay using washed platelets derived from an HIT diagnostic functional assay. VITT is a very rare life-threatening adverse event. Further studies are needed to investigate the prevalence of this coagulopathy associated with multiple thromboses after ChAdOx1 nCov-19 or Ad26.COV2.S COVID-19 vaccines and for other vaccines to decipher the particular populations that need to be vaccinated with mRNA or adenovirus vaccines. We would like to acknowledge all nurses, technicians, and physicians None of these conflicts are related to this paper: RC received con- Is COVID-19 a new hematologic disease? Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients Circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality Curative anticoagulation prevents endothelial lesion in COVID-19 patients Anticoagulation prior to hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study COVID-19 is, in the end, an endothelial disease Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase Thrombotic thrombocytopenia after ChAdOx1 nCov-19 Vaccination Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination Thrombotic thrombocytopenia after Ad26.COV2.S vaccination Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass The platelet serotoninrelease assay Identifying patients at high risk of heparin-induced thrombocytopenia-associated thrombosis with a platelet activation assay using flow cytometry Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology Platelets: a critical link between inflammation and microvascular dysfunction